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Many diagnostic and therapeutic procedures in children such as 
electroencephalography, computed tomography scan, magnetic resonance imaging, 
echocardiography, lumbar puncture, instrumentation (endoscopy, bronchoscopy,…), 
reduction of fracture, repair of laceration, abscess drainage, burn dressing 
change, and chest tube or central line placement are needed. Procedural sedation and 
reduction of pain and anxiety outside the operating room have been emphasized (1). 
Aims of procedural sedation include maintenance of patient’s safety and welfare, 
physical pain, discomfort and psychological trauma, anxiety and 
behavior control, amnesia maximization and reduce movement for safe performance 
of procedures. To make pediatric procedural sedation as safe as possible, protocols 
which specify a pre-sedation evaluation including a sedation plan, during the 
procedure and recovery monitoring, discharge and follow-up criteria, personnel 
credentialing, and an improvement of quality monitoring mechanism, should be 
developed by institutions. Providers of health care who carry out procedural sedation 
in children must have strong resuscitation and highly advanced pediatric life 
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support skills including necessary training in assessing 
and management of the pediatric airway. Besides, they 
should have specific training in pediatric procedural 
sedation (2).
In this narrative review article, we have verified 
non-parenteral medications that can be used by non- 
anesthesiologist.
Search strategy
This narrative review study was conducted in 2014. 
Required data were collected through searching 
for key words included: “ Sedation” , “Children”,” 
Procedural sedation” , Non-parenteral medications “ 
and their Per¬sian equivalents using databases including 
Pub¬Med, OVID,  Embase, Scopus, Magiran, scientific 
information database (SID), Google Search engine, and 
also Nelson Textbook of Pediatrics. To increase the 
confidence in the selection of articles, the reference lists 
of the articles, certain relevant journals and web site of 
up to date (www. uptodate.com ) in this field also were 
searched. 
Results
Levels of sedation are defined as follows:
Minimal sedation: Response of the patient is normal to 
verbal commands. Cognitive function and coordination 
might be impaired, but ventilatory and cardiovascular 
functions are not affected. 
Moderate sedation: The patient has consciousness 
depression but can respond to verbal commands 
either alone or accompanied by light touch, maintains 
airway and enough ventilation without intervention and 
cardiovascular function is also maintained. 
Deep sedation: The patient does not easily arouse but 
responds purposefully to noxious stimulation, may 
need help to maintain airway and adequate ventilation. 
Cardiovascular function is usually maintained (2, 3).
The Joint Commission recommends that providers have 
the capability of one level deeper than the target depth 
for patients’ management (3). Response to sedation in 
children is highly variable, while some become deeply 
sedated after minimal doses, others may need much 
higher doses. In addition, differentiation of sedation 
levels may be hard or impossible during a given test or 
procedure for a given patient. 
Indications of procedural sedation in children
There are no definite indications for the performance of 
children procedural sedation. It might be used for any 
procedure in which a child’s pain or anxiety is excessive 
and movement may prevent performance. The sedation 
need will vary highly with a child’s developmental or 
behavioral status. The targeted sedation depth and 
medications selection depends largely on the procedure 
performed the foreseen degree of pain, and patient 
factors (2, 3).
Contraindications of procedural sedation in children
There are no definite contraindications to children 
procedural sedation. Relative contraindications of 
procedural sedation include:
• Signs of a difficult airway or significant medical 
comorbidities [Patients with American Society of 
Anesthesia (ASA) Classification III or higher and 
children with history of severe sleep apnea or airway 
abnormality]
• True allergic reactions to sedative drugs
• Prior paradoxical reactions (patient becomes more 
agitated than sedated) with benzodiazepines or ketamine.
• Children in whom the risk of sedation outweighs the 
benefit 
Risk of aspiration might be increased in children with 
severe gastroesophageal reflux disease and acute 
or chronic decreased gastrointestinal motility and 
continuation of precautions for aspiration is necessary 
at all times.
Pre-sedation evaluation
A: Taking a history
Medical history about medical illnesses ( respiratory, 
cardiovascular, and neurologic systems), snoring or 
central or obstructive sleep apnea, previous exposure to 
sedation or general anesthesia, drug and food allergies, 
current medications, family history of an adverse 
reaction to sedation, analgesia, or general anesthesia, 
and the time and content of their last oral intake should 
be taken. Review of systems that evaluate cardiac, 
pulmonary, renal, bowel and hepatic function should 
also be done (4).
B: ASA Classification
Before sedation, sedation risk assessment, airway 
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assessment and ASA classification should be given to 
each patient as follows: 
Class I: A normally healthy patient 
Class II: A patient with mild to moderate systemic 
disease with no functional limitations (mild chronic renal 
failure, iron deficiency anemia, mild asthma, controlled 
diabetes mellitus) 
Class III: A patient with severe systemic disease with 
functional limitations but is not incapacitating (moderate-
to-severe asthma, poorly controlled diabetes mellitus, 
pneumonia, congenital heart disease, cystic fibrosis)
Class IV: A patient with incapacitating systemic disease 
that is a constant threat to life (severe bronchopulmonary 
dysplasia, advanced cardiac disease) 
Class V: A moribund patient who is not expected to 
survive 24 hours, with or without surgery (septic shock, 
severe trauma)
Class VI: A clinically dead patient being maintained for 
harvesting organs.
Children with ASA classes I and II are generally 
reasonable candidates for mild, moderate, and deep 
sedation by the personnel other than anesthesiologists, 
outside of the operating room. Those patients with 
ASA classes III, IV, and V, special needs, or airway 
abnormalities warrant consultation with a pediatric 
anesthesiologist or pediatric critical care specialists or 
pediatric emergency medicine specialists (2). 
C: Obtaining written informed consent from the primary 
caregiver 
Before performing procedural sedation, the clinician 
should be ensured that monitoring devices are present and 
functioning properly and that oxygen, oxygen delivery 
devices, suction catheters and apparatus, pediatric airway 
equipment (laryngoscope with appropriately sized 
blades, endotracheal tubes and laryngeal mask airway), 
an emergency cart with appropriate medications, and 
a defibrillator are immediately available and obtain 
informed consent from the patient or the primary 
caregiver and the specific medications that will be 
administered. Potential routes of administration for 
procedural sedation and alternatives such as regional 
anesthesia or general anesthesia, potential side effects 
(vomiting, respiratory depression, laryngospasm, 
emergence reaction), and the likely duration of sedation 
should be explained. 
Because depression of consciousness is a continuum 
and responses to medications vary, clinicians must 
be able to deal with complications in patients whose 
level of sedation becomes deeper than intended or who 
experience an adverse reaction to medication (5, 6).
D: Fasting
ASA suggests that children undergoing sedation for 
scheduled elective procedures outside of the operating 
room, to fast as follows: two hours for clear liquids, 
four hours after breast feeding, six hours for solid foods, 
formula, or non- human milk. However, there is little 
evidence that this approach actually prevents aspiration 
(5).
Based on the National Institute for Health and Clinical 
Excellence guidance, fasting is not needed for sedation 
with 50% nitrous oxide (in oxygen) alone and for 
moderate sedation where the child maintains verbal 
contact. Fasting based on the ASA guideline is advised 
for patients with moderate sedation where the child 
might not maintain verbal contact and deep sedation (6).
E: Performing procedural sedation 
Performing of sedation requires at least two individuals, 
typically an advanced practice clinician (eg, physician, 
physician’s assistant, advanced practice registered 
nurse, nurse anesthetist) and an assistant. At least one 
present person should be trained in advanced pediatric 
life support and be skilled in airway management and 
cardiopulmonary resuscitation. 
1: Monitoring
Vital signs (pulse rate, respiratory rate and blood pressure) 
should be recorded before starting the procedure, after 
description of sedative drugs, at completion of the 
procedure, during early recovery and at completion of 
recovery (3). 
Level of consciousness, drugs that is administrated, and 
any complications that may be occurred, should be 
monitored continuously.
Monitoring equipment appropriate to the degree of 
sedation should be ready for use as follows:
•    Mild sedation: Pulse oximetry and heart rate 
• Moderate or deep sedation: Pulse oximetry, 
capnography or continuous visual monitoring of 
breathing (face, mouth, and chest wall movement), heart 
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condition of the child, type of procedure, and predicted 
pain degree. Non- painful procedures that require 
immobility of the child can be done with sedation alone. 
However, painful procedures require analgesia as well 
as sedation. Drugs might be administered parenteral 
(intravenous or intramuscular) or non- parenteral 
including oral, rectal, sublingual, aerosolized buccal and 
intranasal.
The use of intravenous medication such propofol, 
ketamine, dexmedetomidine, or etomidate may be 
restricted to use by anesthesiologists or other specialists. 
We discuss non-parenteral medications here.
Non-parenteral sedative drugs 
* Promethazine
Promethazine is a cheap and easily available 
antihistamine with antiemetic properties, which might 
be used for sedation induction, especially in regions that 
chloral hydrate is unavailable (8, 9). 
In a study in Yazd, Iran, adequate sedation and successful 
electroencephalography recording were obtained in 70% 
of children with ASA class I or II who received 1 mg/kg 
of promethazine (8).
* Chloral hydrate 
Chloral hydrate is a non-opiate, non-benzodiazepines 
sedative hypnotic drug, used for pediatric sedation 
in dosage of 40-100 mg/kg for years especially for 
diagnostic imaging in infants and in younger than three-
year-old children image. It can be administered orally 
or rectally and action onset of a single dose of chloral 
hydrate takes up to 30 minutes and up to 60 minutes 
while re-dosing is necessary. The onset and degree of 
sedation may be undependable with the rectal route. 
Time to discharge is 5 to 10 days with the longer time 
occurring in children who need re-dosing (8-13). 
The drug is contraindicated in children with kidney, liver, 
or cardiovascular disease. It should not be administered 
by oral in children with gastritis, esophagitis, or 
peptic ulcers in view of mucosal irritation. Side 
effects include gastrointestinal irritation and vomiting 
with oral use, excessive sleepiness and prolonged 
sedation, hallucinations and paradoxical agitation, 
airway obstruction, respiratory depression and oxygen 
desaturation, postprocedural bradycardia, especially in 
rate, respirations, and blood pressure
2: Vascular access
Children that receive deep sedation should have an 
intravenous catheter in place for administration of 
multiple doses of drugs or for resuscitation, if needed. 
Although desirable intravenous access is mandatory 
neither for lighter levels of sedation nor when sedative 
agents are given by oral, nasal, rectal, or intramuscular 
routes. If the procedure is performed without an 
intravenous catheter, equipment and personnel capable 
of establishing vascular access should be immediately 
available3: Selection of procedural sedation 
intervention in children
Developmental status of child, clinical circumstances 
and condition of patient should be considered and then 
pharmacologic and nonpharmacologic interventions for 
sedation are selected (1).
Nonpharmacologic interventions 
For many children, non-pharmacologic interventions use 
(behavioral and cognitive approaches) might prevent the 
need for procedural sedation. In conscious situations of 
the patient during the sedation, behavioral and cognitive 
approaches are complementary to pharmacologic 
interventions and must be used. These techniques aid 
to reduce preprocedural agitation which lets an easier 
transition to sedation as well, may decrease the amount 
of medication needed for effective sedation, and may 
cut adverse events frequency, including emergence 
phenomena. 
Behavioral treatments include desensitization 
techniques, distraction (non-nutritive sucking in 
infants, bubble blowing, party blowers, listening to a 
book, counting, interactive toys, playing music through 
headphones, video games, and videotapes), reinforcing 
coping skills, positive reinforcement, and relaxation 
techniques (2, 7). 
Parental involvement increases the effect of behavioral 
pain management if the parent is properly prepared for 
a positive role and managing of parental anxiety is an 
important element in allaying a child’s fears (7).
Pharmacologic medications for pediatric procedural 
sedation 
Drug of choice and administration route depend on the 
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young term and preterm infants and tachyarrhythmia 
with excessive and higher dosage (14, 15).
Monitoring procedural sedation protocols must be 
followed for all patients receiving chloral hydrate. As 
there is no consistent dose, below which complications 
do not happen (3) and in young infants, up to 12 hours 
observation after chloral hydrate sedation may be 
necessary prior to safe discharge (16). In two other 
studies in Yazd, Iran, combination of chloral hydrate 
and antihistamines (hydroxyzine or promethazine) 
was an effective and safe sedation regimen in children 
(9, 10). Some countries have put aside chloral hydrate 
from their national health formularies due to potential 
carcinogenicity even if the risk of cancer from a single 
dose is inconclusive (17).
* Midazolam 
Midazolam is a short-acting water soluble 
benzodiazepine with anxiolytic and amnestic properties 
that can be used orally, rectal, sublingual, aerosolized 
buccal, intranasal, intravenous or intramuscular that 
dosage, effect duration and onset of action depends on 
child age and administration method and action duration 
of midazolam is shorter than pentobarbital or chloral 
hydrate (3, 11, 13, 17-19).
Intranasal rout has the most rapid onset of action and 
shortest recovery time in comparison to oral, rectal or 
sublingual administration. Rectal midazolam is less 
dependable and may arouse patient discomfort. Since, 
intranasal midazolam might be irritant in a few patients, 
administration of 10 mg per puff of lidocaine spray, one 
minute before prescription of intranasal midazolam can 
reduce nasal mucosal irritation (20). 
Ampoule of midazolam can be used orally or intranasal 
when oral or intranasal midazolam is not available (18). 
Injectable midazolam given orally in dose of 0.75 mg/
kg as a premedication was effective in Sheta et al. study 
(21). Dosage of oral midazolam in children is 0.5 – 1 
mg/kg (22) and dose of intranasal midazolam is 0.2-0.5 
mg/kg (11, 23). 
Action onset of oral, sublingual and intranasal midazolam 
is similar (5-10 minutes), but sedation duration of 
intranasal midazolam is shorter (20-30 minutes) and 
recovery time of oral or sublingual is approximately 
60 minutes. Unlike barbiturates or chloral hydrate, 
midazolam is not associated with prolonged symptoms 
of ataxia, sleepiness, or irritability (24, 25). 
Common side effects include respiratory depression 
or apnea, especially when used with opioids or other 
sedative drugs, and paradoxical reactions (hyperactivity, 
aggressive behavior and inconsolable crying). 
Midazolam has mild negative inotropic effects. It must 
be administered with caution in children with underlying 
myocardial depression. Respiratory depression or 
apnea and paradoxical reactions can be reversed with 
flumazenil. Nevertheless, flumazenil must not be used 
in patients with seizure disorders or in those who 
receive benzodiazepines on a chronic basis due to the 
risk of precipitating seizures or withdrawal symptoms, 
respectively (3).
* Melatonin
Melatonin is an indoleamine and useful oral natural-
sleep agent. Its main role is modulation of the circadian 
rhythm of, sleep, and can be used as a safe and effective 
sedative drug in procedures of children. In two 
studies in children, adequate sedation and successful 
electroencephalography recording was achieved in 73% 
of 1-8 year old ones who did not naturally sleep and 
immobilized and were in ASA class I or II (18, 26, 27).
* Short-acting barbiturates
Pentobarbital, methohexital, and thiopental are short-
acting barbiturates that induce sedation by inhibiting 
gamma-aminobutyric acid receptors in the central 
nervous system and pentobarbital has the best efficacy 
and fewest adverse effects. Dosage of orally or rectally 
pentobarbital is 3 to 6 mg/kg in less than four year old 
children and 1.5 to 3 mg/kg in four year old and older 
ones and maximum single dose is 100 mg.
Methohexital and thiopental  can be used rectally. Dosage 
of rectal methohexital is 25 mg/kg with maximum 500 
mg. It can cause seizures in children with epilepsy and 
should be avoided in these patients. Dosage of rectal 
thiopental is 5 to 30 mg/kg with maximum 700 mg.
Common side effects of short-acting barbiturates are 
respiratory depression, hypotension, and myocardial 
depression. Pentobarbital has the lowest risk of 
respiratory depression and rectal thiopental has the 
highest risk. The potential for airway compromise 
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rises while barbiturates are used combined with 
other sedatives or opioids. Prolonged sleepiness is 
common after pentobarbital administration. Absolute 
contraindications of use of barbiturates are porphyria 
and its relative contraindications include cardiac, liver, 
or renal insufficiency and the drugs should be avoided in 
patients with hemodynamic instability or heart failure. 
Methohexital may cause seizures in children with 
epilepsy. It must not be used in such patients (28, 29).
* Dexmedetomidine 
Dexmedetomidine is a selective alpha-2 adrenergic 
receptor agonist that can be used by intranasal, oral or 
buccal routes for pediatric sedation and it causes minimal 
respiratory depression. In healthy children, it can be 
used as a safe and effective and is the preferred drug for 
sedation induction in diagnostic imaging (30, 31).
Effectiveness of 0.5 mg/kg oral midazolam or 1.5 mcg/
kg of intranasal dexmedetomidine in sedation induction 
was equal, but, intranasal dexmedetomidine was 
accompanied with less post-procedural pain scores (32) 
and perioperative administration of 3 to 4 mcg/kg buccal 
dexmedetomidine showed moderate sedation without 
respiratory complications (33, 34) .
Side effects of dexmedetomidine include: 
• Hypertension might be seen in up to 5% of patients 
that take continuous infusion of dexmedetomidine and 
typically resolves without specific treatment.
• Moderate bradycardia and hypotension might occur 
in up to 30% of children who receive dexmedetomidine 
continuous infusion and hypotension is usually reversed 
with a fluid bolus.
Dexmedetomidine is contraindicated in children who 
receive medicines with rate slowing action on the AV 
node (digoxin, nifedipine ), cardiac conduction system 
pathology, and those in whom increased pulmonary 
artery pressure or decreased cardiac output are unlikely 
to be well tolerated (eg, right-sided heart failure, septic 
shock) and relative contraindications include children 
who are debilitated, inadequately hydrated, or have 
reduced cardiac output (35, 36).
* Ketamine
Ketamine is a derivative of phencyclidine with the 
impact that is either present or absent and provides 
sedation, analgesia, amnesia, and immobilization, while 
usually preserve upper airway muscle tone, airway 
protective reflexes, and spontaneous breathing and the 
drug can be administered intranasal or oral for children 
premedication (37-39).
F: Discharge criteria
Returning to the level of responsiveness in handicapped 
young infants or children, should be observed before 
sedation. Monitoring must continue until the child meets 
the criteria for safe discharge including airway patency 
and stable cardiovascular function, easy arousability with 
intact protective reflexes, talk ability, unaided ability to 
sit up and maintain wakefulness, enough hydration with 
any nausea or vomiting management and also right 
management of any continued pain (40).
The minimum observation duration of infants, include:
• All term or pre-term infants with post conceptual 
ages (PCA) ≤45 weeks : 12 hours 
• Pre-term infants with PCA 46 to 60 weeks and 
important comorbidities : 12 hours 
• Healthy pre-term infants with PCA 46 to 60 weeks: 
6 hours (12 hours if prescribed opioids or other 
medications with notable respiratory depressant 
effects) (41, 42).
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